Company Overview and News

Conatus Pharmaceuticals: A Long-Term Play In The Rapidly Expanding NASH Market

2018-02-07 seekingalpha
Conatus Pharmaceuticals is currently in Phase 2 trials (data expected 2018-2019) for its NASH drug emricasan, which has received Fast Track designation from the FDA.

Notable BioSci Mover - October 6, 2017 Report

2017-12-07 seekingalpha
Shares of Madrigal Pharmaceuticals catapulted to new high due to robust phase 2 data reporting for NASH.

Liver Fibrosis Therapeutic Development and Pipeline Review H1 2017 Research Report Now Available at RnRMarketResearch

2017-05-23 prnewswire adds "Liver Fibrosis - Pipeline Review, H1 2017" therapeutic market research report of 200 pages with latest updates, data and information to its online business intelligence library.

2 Possible Acquisition Targets For Gilead Sciences

2017-01-27 seekingalpha
M&A activity is seeing a noticeable uptick to start the year compared to a punk 2016 for transactions.

Allergan to buy Tobira in push for NASH treatments

2016-09-20 channelnewsasia
REUTERS: Allergan Plc said it would buy Tobira Therapeutics Inc in a deal worth up to US$1.7 billion, about 19 times the company's current value, to get a leg up in the race to develop therapies for NASH, an incurable fatty liver disease.

Can-Fite Unveils New Indication To Treat NASH The Next Big Global Epidemic

2016-09-19 seekingalpha
The term 'platform technology' gets a lot of play, some of it hype, but when an emerging and scientifically sound biotech company shows promise of multiple uses for its core drug, investors should take notice. This is the case with Can-Fite BioPharma Ltd. (NYSEMKT:CANF), who last month released convincing preclinical data that its CF102, currently in trials for a common form of liver cancer, has a beneficial effect on non-alcoholic steatohepatitis (NYSEARCA:NASH), an insidious disease not readily manifested, making it all the more dangerous.

Pipeline Insights on Nonalcoholic Steatohepatitis Market

2016-09-12 prnewswire adds "Non-Alcoholic Steatohepatitis - Pipeline Review, H2 2016" market research report with comprehensive information on NASH therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

NASH Market (Drugs) to see 25.56% CAGR During 2020 - 2030

2016-05-06 prnewswire
Global NASH market report says progressive numbers of liver disorders along with rise in obesity will fuel the demand for NASH (non-alcoholic steatohepatitis) drugs in the coming few years. The NASH Market is growing at a moderate rate over last five years on account of rising number of obesity among young population. NASH (non-alcoholic steatohepatitis) is a large, un-tapped market with no FDA approved therapeutics.

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market to Reach US$20.27 bn by 2025, Elafibranor Projected to Spur Growth: Transparency Market Research

2016-04-18 prnewswire
According to a new market report published by Transparency Market Research "Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025", the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.

Genfit plans to test its drug in second liver disease

2016-03-31 channelnewsasia
NEW YORK: French drugmaker Genfit SA on Thursday said it would begin a midstage trial this year of its experimental drug elafibranor to treat primary biliary cholangitis, a chronic disease in which bile ducts in the liver are gradually destroyed.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

12h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

12h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

22h - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...